Northwest Biotherapeutics Company Profile (NASDAQ:NWBO)

About Northwest Biotherapeutics (NASDAQ:NWBO)

Northwest Biotherapeutics logoNorthwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NWBO
  • CUSIP: N/A
  • Web:
  • Market Cap: $48.27 million
  • Outstanding Shares: 186,061,000
Average Prices:
  • 50 Day Moving Avg: $0.18
  • 200 Day Moving Avg: $0.19
  • 52 Week Range: $0.14 - $0.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.10
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $386,000.00
  • Price / Sales: 78.81
  • Book Value: ($0.15) per share
  • Price / Book: -1.10
  • EBITDA: ($69,120,000.00)
  • Net Margins: -11,651.14%
  • Return on Assets: -85.95%
  • Current Ratio: 0.04%
  • Quick Ratio: 0.04%
  • Average Volume: 1.68 million shs.
  • Beta: 1.75
  • Short Ratio: 13.54

Frequently Asked Questions for Northwest Biotherapeutics (NASDAQ:NWBO)

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the NASDAQ under the ticker symbol "NWBO."

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.22. The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.20 million. View Northwest Biotherapeutics' Earnings History.

Where is Northwest Biotherapeutics' stock going? Where will Northwest Biotherapeutics' stock price be in 2017?

0 brokers have issued 12 month price targets for Northwest Biotherapeutics' shares. Their predictions range from $0.61 to $0.61. On average, they anticipate Northwest Biotherapeutics' stock price to reach $0.61 in the next twelve months. View Analyst Ratings for Northwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the folowing people:

  • Linda F. Powers, Chairperson of the Board, President, Chief Executive Officer
  • Leslie J. Goldman, Senior Vice President - Business Development
  • Anthony E. Maida Ph.D., Senior Vice President - Clinical Research
  • Marnix L. Bosch Ph.D, Chief Technical Officer
  • Alton L. Boynton Ph.D., Chief Scientific Officer, Director
  • Susan B. Bayh, Independent Director
  • Cofer Black, Independent Director
  • Robert A. Farmer, Independent Director
  • Jerry J. Jasinowski, Independent Director
  • Navid Malik, Independent Director

How do I buy Northwest Biotherapeutics stock?

Shares of Northwest Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of Northwest Biotherapeutics stock can currently be purchased for approximately $0.16.

MarketBeat Community Rating for Northwest Biotherapeutics (NASDAQ NWBO)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Northwest Biotherapeutics (NASDAQ:NWBO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $0.61 (273.09% upside)
Consensus Price Target History for Northwest Biotherapeutics (NASDAQ:NWBO)
Price Target History for Northwest Biotherapeutics (NASDAQ:NWBO)
Analysts' Ratings History for Northwest Biotherapeutics (NASDAQ:NWBO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/15/2016S&P Equity ResearchLower Price Target$0.73 -> $0.61N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Northwest Biotherapeutics (NASDAQ:NWBO)
Earnings by Quarter for Northwest Biotherapeutics (NASDAQ:NWBO)
Earnings History by Quarter for Northwest Biotherapeutics (NASDAQ NWBO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2015Q2 2015($0.32)($0.54)$0.20 million$0.39 millionViewN/AView Earnings Details
8/15/2014Q2 2014($0.29)($0.53)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.33)($0.46)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Northwest Biotherapeutics (NASDAQ:NWBO)
Current Year EPS Consensus Estimate: $-1.8500 EPS
Next Year EPS Consensus Estimate: $-1.6000 EPS


Dividend History for Northwest Biotherapeutics (NASDAQ:NWBO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Northwest Biotherapeutics (NASDAQ:NWBO)
No insider trades for this company have been tracked by


Headline Trends for Northwest Biotherapeutics (NASDAQ:NWBO)
Latest Headlines for Northwest Biotherapeutics (NASDAQ:NWBO)
DateHeadline logoNW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm - October 18 at 7:48 AM logoNW BIO Announces Registered Direct Offering Of $1.75 Million - September 22 at 12:00 PM logoETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017 - September 6 at 7:05 AM logoDCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference - September 2 at 6:57 AM logoNorthwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 - August 25 at 9:29 AM logoNorthwest Biotherapeutics: Statistically Satisfying - Seeking Alpha - August 24 at 10:22 AM logoWoodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... - May 23 at 6:29 PM logoNovocure Glioblastoma Drug Offers Survival Benefits - April 3 at 6:17 PM logoBiotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma - March 31 at 9:08 AM logoNorthwest closes $7.5M capital raise - Seeking Alpha - March 24 at 11:52 PM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an - March 23 at 7:28 PM logoNW BIO Announces Registered Direct Offering Of $7.5 Million - March 17 at 7:06 PM logoNorthwest Biotherapeutics agrees to pay bondholders $11 million, needs cash - March 16 at 7:40 PM logoBRIEF-NW Bio reaches agreement with convertible note holders - March 10 at 8:41 PM logo8:16 am Northwest Biotherapeutics signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors, holder of $11 mln of the co's convertible senior notes - March 10 at 8:41 PM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi - March 7 at 6:47 PM logoBiotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics - February 21 at 5:56 PM logoFDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial - February 9 at 8:01 PM logoNorthwest Bio Spikes on Lifting of Clinical Hold (NWBO) - February 7 at 9:32 PM logoFDA Lifts Hold on Northwest Bio Cancer Drug Trial - February 7 at 4:30 PM logoBRIEF-NW bio announces lifting of clinical hold on DCVax -l phase III trial by FDA - February 6 at 7:01 PM logoFlu Case Grinds Small Biotech to a Halt - January 23 at 7:17 PM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure - January 23 at 9:49 AM



Northwest Biotherapeutics (NWBO) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.